Filtered By:
Drug: Rosuvastatin

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 159 results found since Jan 2013.

Acute dysphagia: A rare initial symptom of lateral medullary syndrome: A case report
CONCLUSION: The diagnosis of LMS was queried owing to the presentation of the single most important common symptom, with no other characteristic manifestations of LMS.PMID:36582892 | PMC:PMC9793181 | DOI:10.1016/j.amsu.2022.104851
Source: Annals of Medicine - December 30, 2022 Category: Internal Medicine Authors: Farhan Ali Amraha Zubair Fatima Nazir Kashif Ali Sobia Mansoor Source Type: research

Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Conclusions In this small, open-label, randomised trial of non-critically ill hospitalised patients with COVID-19, the combination of colchicine and rosuvastatin in addition to standard of care did not appear to reduce the risk of progression of COVID-19 disease or thromboembolic events, although the trial was underpowered due to a lower-than-expected event rate. The trial leveraged the power of electronic medical records for efficiency and improved follow-up and demonstrates the utility of incorporating electronic medical records into future trials. Trial registration NCT04472611.
Source: BMJ Open - February 24, 2023 Category: General Medicine Authors: Shah, T., McCarthy, M., Nasir, I., Archer, H., Ragheb, E., Kluger, J., Kashyap, N., Paredes, C., Patel, P., Lu, J., Kandel, P., Song, C., Khan, M., Huang, H., Ul Haq, F., Ahmad, R., Howes, C., Cambi, B., Lancaster, G., Cleman, M., Dela Cruz, C., Parise, H Tags: Open access, Infectious diseases, COVID-19 Source Type: research

The effect of bempedoic acid an ATP-citrate lyase inhibitor on cardiovascular risk factors in rats with experimentally induced myocardial infarction and hyperlipidemia
Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(10):94-99. doi: 10.14715/cmb/2022.68.10.15.ABSTRACTControl of hyperlipidemia is believed to reduce major cardiovascular events such as cardiovascular death, myocardial infarction, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization. The benefits of monotherapy with Bempedoic acid (BA) as a hypolipidemic agent given after induction of myocardial infarction (MI) in reducing the risk of acute MI worth being investigated, therefore this study was designed to investigate the effectiveness of Bempedoic acid on reducing cardiovascular risk factors in ...
Source: Mol Biol Cell - April 28, 2023 Category: Molecular Biology Authors: Mahmood Salim Yaseen Nidhal Mohammed Ali Source Type: research

Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research